Long-term acute care hospitals provide better outcomes and more cost-effective care when treating critically ill and medically complex patients.
A new study published in Medical Care found that long-term acute care hospitals (LTCH) provide better outcomes and more cost-effective care when treating critically ill and medically complex patients.
Researchers from the National Association of Long Term Hospitals (NALTH) examined non-ventilator patients with multiple organ failures who spent 3 days or more in an LTCH intensive care unit. Of this population, the authors of the study discovered that the patients had similar or lower Medicare costs as well as lower mortality rates.
By comparing LTCH patients to those in other skilled nursing facilities and inpatient rehabilitation facilities, researchers found that Medicare costs differed specifically for patients at an LTCH with circulatory, digestive and musculoskeletal and connective tissue conditions. These patients had lower costs ranging from $13,806 to $20,809.
"As our population ages and the incidence of chronic disease increases, critically ill and medically complex patients will represent a growing segment of the Medicare population," Lane Koenig, PhD, director of Policy and Research for NALTH, and the study's lead author, said in a statement. "Because care for these patients requires a significant amount of healthcare resources, it's important to identify cost-effective treatment approaches."
The study identified 5 diagnostic categories using Medicare data from 2009-2010, which included respiratory, circulatory, digestive, musculoskeletal, and connective tissues, and further examined high severity cases. Researchers reported that LTCH care was the superior treatment option for 7 of the 10 research groups, while another group demonstrated reduced mortality but at a higher cost.
"LTCHs must be part of the conversation as payers seek ways to improve outcomes and reduce treatment costs for patients with significant illnesses," Cheryl Burzynski, NALTH president, added.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More